Sorrento Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sorrento Therapeutics, Inc.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Sorrento and Mabpharm have revealed plans to take their infliximab “biobetter” global, after China’s NMPA approved the product, which has an improved safety profile compared to Remicade.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
- Medical Devices
- Specialty Pharmaceuticals
- Site Specific
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Large Molecule
- Other Names / Subsidiaries
- ADNAB, Inc.
- Levena (Suzhou) Biopharma Co., Ltd
- SCILEX Pharmaceuticals, Inc.
- Scilex Holding Company
- Scintilla Pharmaceuticals, Inc.
- Semnur Pharmaceuticals, Inc.
- Sherrington Pharmaceuticals
- SmartPharm Therapeutics, Inc.
- TNK Therapeutics, Inc.
- Virttu Biologics Limited